Andrew Foxley, BA on A Phase III Trial of Capivasertib and Paclitaxel: More on the Design #ASCO2020 @AstraZeneca #ASCO

Andrew Foxley, BA of AstraZeneca @AstraZeneca discusses a phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer.

Read here:https://meetinglibrary.asco.org/record/191881/abstract